Autolus therapeutics presents clinical data updates at the american society of hematology (ash) annual meeting 2024

London, dec. 09, 2024 (globe newswire) -- autolus therapeutics plc (nasdaq: autl), an early commercial-stage biopharmaceutical company developing next-generation programmed t cell therapies, announces an oral presentation and three poster presentations at the american society of hematology (ash) annual meeting, being held from december 7-10, 2024, in san diego. “our oral presentation at ash this year with data from the felix trial demonstrates that obe-cel treatment produces a high incidence of deep molecular remission in r/r adult all patients, which correlates with better outcomes and is associated with longer event free survival (efs) and overall survival (os),” said dr. christian itin, chief executive officer of autolus.
ASH Ratings Summary
ASH Quant Ranking